Zhitong Finance App News, Cornerstone Pharmaceutical-B (02616.HK) announced that the company has reached a cooperation with Kimia Therapeutics, Inc. (“Kimia”), a biopharmaceutical company focusing on the development of innovative oncology and immunology drugs. The two sides will jointly advance the clinical development of a solid tumor drug candidate with similar pioneering potential and targeting the DNA damage response (DDR) pathway critical to solid tumor survival. Cornerstone Pharmaceuticals will lead the clinical development of this candidate in mainland China and Australia.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.